Reconsidering 'minimal risk' to expand the repertoire of trials with waiver of informed consent for research

被引:7
作者
Monach, Paul A. [1 ]
Branch-Elliman, Westyn [2 ]
机构
[1] VA Boston Hlth Care Syst, Rheumatol Sect, Jamaica Plain Campus, Boston, MA USA
[2] VA Boston Hlth Care Syst, Infect Dis Sect, West Roxbury Campus, West Roxbury, MA 02132 USA
来源
BMJ OPEN | 2021年 / 11卷 / 09期
关键词
clinical trials; ethics (see medical ethics); statistics & research methods; HEALTH-CARE-SYSTEM; CLINICAL-TRIALS;
D O I
10.1136/bmjopen-2020-048534
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Progress in therapeutic research is slowed by the regulatory burden of clinical trials, which provide the best evidence for guiding treatment. There is a long delay from evidence generation to adoption, highlighting the need for designs that link evidence generation to implementation. Objective To identify clinical trial designs that confer minimal risk above that inherent in clinical care, to obviate the need for cumbersome consenting processes to enrol patients in prospective clinical research studies. These designs extend the scope of the Learning Healthcare System, a framework for leveraging retrospective 'big data' to advance clinical research, to include data collected from prospective controlled trials. Pragmatic trials may use simplified eligibility criteria, unblinded interventions and objective outcome measures that can all be monitored through the electronic health records (EHR), to reduce costs and speed study conduct. Most pragmatic trials continue to suffer from substantial regulatory burden. Written consent to participate in research can be waived only if the research produces minimal risk above what is encountered in everyday life. However, the 'consent' processes for prescribing Federal Drug Administration-approved medications in clinical medicine are informal, even when they involve decisions of uncertain benefit and higher levels of risk. We propose that trial designs that mimic clinical decision-making in areas of uncertainty (clinical equipoise) and in which no data are generated outside of usual care (ideally by EHR embedding) confer minimal additional risk. Trial designs meeting this standard could, therefore, be conducted with minimal documentation of consent, even when interventions contain different risks. To align with risk encountered in clinical practice, allocation to treatment arms should change (adaptive randomisation) as data are collected and analysed. Embedding of informatics tools into the EHR has the additional benefit that, as adaptive randomisation progresses, evidence-generation transitions into implementation via decision-support tools-the ultimate realisation of the Learning Healthcare System.
引用
收藏
页数:7
相关论文
共 21 条
  • [1] The Food and Drug Administration and pragmatic clinical trials of marketed medical products
    Anderson, Monique L.
    Griffin, Joseph
    Goldkind, Sara F.
    Zeitler, Emily P.
    Wing, Liz
    Al-Khatib, Sana M.
    Sherman, Rachel E.
    [J]. CLINICAL TRIALS, 2015, 12 (05) : 511 - 519
  • [2] How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols
    Asundi, Archana
    Resnik, Jack
    Benedict, Peter A.
    Shin, Marlena
    Elwy, A. Rani
    Branch-Elliman, Westyn
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (04):
  • [3] Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence
    Bartlett, Victoria L.
    Dhruva, Sanket S.
    Shah, Nilay D.
    Ryan, Patrick
    Ross, Joseph S.
    [J]. JAMA NETWORK OPEN, 2019, 2 (10)
  • [4] Partnering with health system operations leadership to develop a controlled implementation trial
    Bauer, Mark S.
    Miller, Christopher
    Kim, Bo
    Lew, Robert
    Weaver, Kendra
    Coldwell, Craig
    Henderson, Kathy
    Holmes, Sally
    Seibert, Marjorie Nealon
    Stolzmann, Kelly
    Elwy, A. Rani
    Kirchner, JoAnn
    [J]. IMPLEMENTATION SCIENCE, 2016, 11
  • [5] Bringing New Meaning to the Term "Adaptive Trial": Challenges of Conducting Clinical Research During the Coronavirus Disease 2019 Pandemic and Implications for Implementation Science
    Branch-Elliman, Westyn
    Elwy, A. Rani
    Monach, Paul
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (11):
  • [6] Convergence of Implementation Science, Precision Medicine, and the Learning Health Care System A New Model for Biomedical Research
    Chambers, David A.
    Feero, W. Gregory
    Khoury, Muin J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (18): : 1941 - 1942
  • [7] Effectiveness-implementation Hybrid Designs Combining Elements of Clinical Effectiveness and Implementation Research to Enhance Public Health Impact
    Curran, Geoffrey M.
    Bauer, Mark
    Mittman, Brian
    Pyne, Jeffrey M.
    Stetler, Cheryl
    [J]. MEDICAL CARE, 2012, 50 (03) : 217 - 226
  • [8] Informed Consent, Comparative Effectiveness, and Learning Health Care
    Faden, Ruth R.
    Beauchamp, Tom L.
    Kass, Nancy E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (08) : 766 - 768
  • [9] An Ethics Framework for a Learning Health Care System: A Departure from Traditional Research Ethics and Clinical Ethics
    Faden, Ruth R.
    Kass, Nancy E.
    Goodman, Steven N.
    Pronovost, Peter
    Tunis, Sean
    Beauchamp, Tom L.
    [J]. HASTINGS CENTER REPORT, 2013, 43 : S16 - S27
  • [10] Pragmatic Trials
    Ford, Ian
    Norrie, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (05) : 454 - 463